• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Three-year observational study on the ​long-term efficacy and safety of dupilumab in elderly patients with severe atopic dermatitis.

作者信息

Chiei-Gallo Alessandra, Barei Francesca, Calzari Paolo, Pisapia Armando, Marzano Angelo V, Ferrucci Silvia M

机构信息

Department of Pathophysiology and Transplantation, Università degli Studi Di Milano, Milan, Italy.

Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

出版信息

Clin Exp Dermatol. 2025 Feb 24;50(3):659-662. doi: 10.1093/ced/llae420.

DOI:10.1093/ced/llae420
PMID:39388584
Abstract
摘要

相似文献

1
Three-year observational study on the ​long-term efficacy and safety of dupilumab in elderly patients with severe atopic dermatitis.度普利尤单抗治疗老年重度特应性皮炎患者长期疗效及安全性的三年观察性研究
Clin Exp Dermatol. 2025 Feb 24;50(3):659-662. doi: 10.1093/ced/llae420.
2
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
3
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).度普利尤单抗治疗青少年中重度特应性皮炎的长期疗效和安全性：III 期开放标签扩展试验（LIBERTY AD PED-OLE）的第 52 周结果。
Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14.
4
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.度普利尤单抗治疗 6 个月至 5 岁中重度特应性皮炎患儿 1 年的安全性和疗效：一项开放标签扩展研究的结果。
Am J Clin Dermatol. 2024 Jul;25(4):655-668. doi: 10.1007/s40257-024-00859-y. Epub 2024 May 14.
5
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗中重度特应性皮炎的长期管理（LIBERTY AD CHRONOS）：一项为期 1 年、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.
6
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.在长达 4 年的时间里，接受度普利尤单抗治疗的中重度特应性皮炎成人患者的总体感染风险没有增加。
Adv Ther. 2023 Jan;40(1):367-380. doi: 10.1007/s12325-022-02322-y. Epub 2022 Nov 1.
7
One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis.对接受度普利尤单抗治疗特应性皮炎患者的GLOBOSTAD多国前瞻性观察性研究的一年洞察
Adv Ther. 2025 Feb;42(2):720-733. doi: 10.1007/s12325-024-03049-8. Epub 2024 Dec 2.
8
Safety of dupilumab in patients with atopic dermatitis: expert opinion.治疗特应性皮炎患者的度普利尤单抗的安全性：专家意见。
Expert Opin Drug Saf. 2021 Sep;20(9):997-1004. doi: 10.1080/14740338.2021.1939673. Epub 2021 Jun 19.
9
Long-term efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a prospective real-world cohort study in China.度普利尤单抗治疗中重度特应性皮炎的长期疗效和安全性：中国前瞻性真实世界队列研究。
Front Immunol. 2024 Nov 1;15:1419164. doi: 10.3389/fimmu.2024.1419164. eCollection 2024.
10
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis.度普利尤单抗在6至11岁重度特应性皮炎儿童III期开放标签扩展试验中的安全性和有效性。
Dermatol Ther (Heidelb). 2023 Nov;13(11):2697-2719. doi: 10.1007/s13555-023-01016-9. Epub 2023 Sep 26.

引用本文的文献

1
Phenotype-endotype relationship in elderly atopic dermatitis and effects of dupilumab therapy: prospective study.老年特应性皮炎的表型-内型关系及度普利尤单抗治疗的效果：前瞻性研究
Arch Dermatol Res. 2025 Mar 17;317(1):575. doi: 10.1007/s00403-025-04090-5.